Quince Therapeutics shares surge 10.07% intraday after hiring LifeSci Capital as exclusive financial advisor to restructure and evaluate strategic options including partnerships, mergers, or acquisitions.
ByAinvest
Tuesday, Feb 24, 2026 10:42 am ET1min read
QNCX--
Quince Therapeutics surged 10.07% intraday as the company announced hiring LifeSci Capital as an exclusive financial advisor to assist with restructuring and evaluating strategic alternatives, including potential partnerships, joint ventures, mergers, or acquisitions, aiming to maximize shareholder value. The company specializes in leveraging patients' own biology to treat rare diseases, with its core product EryDex developed using the proprietary AIDE technology platform.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet